# Bioidentical Hormones Market

> 生物相似激素市场研究报告信息按类型（雌激素、孕激素和睾酮）、按产品类型（片剂和胶囊、乳膏和凝胶、注射剂以及贴片和植入物）、按最终用户（诊所和医院）以及按地区（北美、欧洲、亚太地区和世界其他地区）–市场预测至2035年

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.7%
- **2024:** $ 2.37 Billion
- **2025:** $ 2.5 Billion
- **2035:** $ 4.36 Billion
- **Key Players:** AbbVie (US), Bayer (DE), Thermo Fisher Scientific (US), Mylan (US), HRT (US), BioTE Medical(US), SottoPelle (US), Compounding Pharmacy of America (US), Women's Health Network (US)

**Report ID:** MRFR/LS/2843-HCR · **Pages:** 80 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** September 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/bioidentical-hormones-market-4187

---

## Market Summary

## **Global Bioidentical Hormones Market Overview**

Bioidentical Hormones Market Size was prized at USD 2.23 Billion in 2023. The bioidentical hormones market is projected to grow from USD 2.37 Billion in 2024 to USD 3.70 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.70% during the forecast period (2024 - 2032). The prevalence of menopausal disorders is on the rise, and women are becoming more aware of the problems associated with post-menopause are the key market drivers enhancing market growth. The market for bioidentical hormones is expected to grow significantly due to recent introductions of hormone replacement treatment.

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

In February 2024, Knight Therapeutics Inc., a specialized pharmaceutical business operating in North and South America (except the United States), announced the introduction of BIJUVA® (estradiol and progesterone) capsules in Canada. BIJUVA® is prescribed to treat menopausal women with an intact uterus who are experiencing moderate to severe vasomotor symptoms (VMS). Vasomotor symptoms (VMS) occur in 60% to 80% of women experiencing menopause and are typically referred to as hot flashes or flushes and night sweats. BIJUVA® is a daily medication that combines bioidentical estradiol and progesterone in a single capsule that is taken orally.

The two hormones present in BIJUVA® possess an identical structure to the hormones naturally produced and circulating throughout a woman's body. BIJUVA® provides women with a convenient solution to manage the difficult symptoms of hot flashes and night sweats that are commonly experienced during menopause. This is achieved through the use of a single oral capsule taken once daily. In July 2018, Knight and TherapeuticsMD entered into a license agreement. According to the agreement, TherapeuticsMD granted Knight the exclusive rights to commercialize BIJUVA® in Canada.

According to the license agreement for BIJUVA® in Canada, Knight will compensate TherapeuticsMD with sales milestone fees and royalties. These payments will be determined by the total yearly sales of BIJUVA® in Canada.

In May 2024, My HealthMatrix Alachua, a branch of Wolf Health Group, commenced operations and is already welcoming new patients. The incorporation of these services is a component of a strategic plan to provide all-encompassing health and longevity services, consolidated in a single facility. The current services provided consist of a 4500 square foot strength training facility that is air-conditioned. This facility offers group classes and personal training, functional rehabilitation, sports performance training, metabolic health and dietary coaching, sports and deep tissue massage, spinal health, and mental health counseling.

The expanded range of services now includes a clinical provider who has received specialized training in health optimization, which encompasses bioidentical hormone replacement therapy, testosterone therapy, pellets, peptides, weight management, thyroid health, thorough health exams, and advanced lab testing. Unlike a typical visit to a regular healthcare facility, your consultation with HealthMatrix Alachua is anticipated to have a duration of up to 2 hours. Our goal is to achieve the highest level of healthcare, rather than focusing solely on treating illness.

By consolidating all the services in a single place, it allows each provider to work together and provide a higher standard of patient care.

## **Bioidentical Hormones Market Trends**

### **Growing prevalence of hormonal deficiencies is driving the market growth**

Market CAGR for bioidentical hormones is driven by the rising number of people suffering from hormonal deficiencies. The commonality of growth hormone and metabolic hormone deficits influences the market. The need for hormone biosimilars is growing as the treatments for illnesses connected to hormones change over time, and hormonal shortages become more common. For example, in January 2022, the British Medical Journal, a peer-reviewed medical trade publication in the UK, reported that the prevalence of GH deficit (GHD) in children is estimated to range from 1 in 3500 to 1 in 10000 worldwide.

Additionally, 6,000 persons in the USA are anticipated to receive a diagnosis of growth hormone (GH) deficiency in June 2022, according to Medscape research. The market for biosimilar hormones is driven by the expanding need to treat individuals with ongoing hormonal deficits.

One of the most prevalent gynecological problems in women is menopause. Contrarily, growth hormone is also thought to be a rare endocrine condition that manifests in adults as a lack of energy, insulin resistance, abnormal lipid levels, and a low level of physical activity. According to Journal of Clinical Endocrinology & Metabolism, Langerhans cell histiocytosis patients have a high prevalence of the growth hormone disorder, which further causes diabetic insipidus and results in growth hormone deficiency in patients with diabetes insipidus. Global acceptance of these medicines has increased due to the rise in adult incidence of hormone insufficiency.

With the right dosage, GHRT shows a low frequency of side effects and improves most GH-deficient changes.  Strong adoption of new goods and successful launch strategies for developing the product line drive market growth during the projection period. With the right dosage, GHRT shows a low frequency of side effects and improves most GH-deficient changes.  Strong adoption of new goods and successful launch strategies for developing the product line drive market growth during the projection period. Thus, driving the bioidentical hormones market revenue.

## **Bioidentical Hormones Market Segment Insights**

### **Bioidentical Hormones Type Insights**

The Bioidentical Hormones Market segmentation, based on type, includes estrogens, progesterone, and testosterone. In 2022, the estrogens segment dominated the market. The dominance was attributed to an increase in the proportion of women going through menopause. As a result, estrogens and their combination aid in treating menopausal symptoms in women by restoring their estrogen levels by introducing external estrogen hormones. Additionally, in 2022, the testosterone segment witnessed the fastest growth rate. Testosterone insufficiency is a prevalent health issue among males between the ages of 40 and 79.

Men over 60 and 70 years old with low testosterone levels make up about 20% and 30% of the male population, respectively. Between 10% and 40% of people worldwide suffer from a testosterone shortage.

**August 2022:** Marius Pharmaceuticals was permitted to market KYZATREX (testosterone undecanoate) by the US Food and Drug Administration. KYZATREX is an oral testosterone replacement treatment ("TRT") approved in adult males for disorders associated with a deficiency or absence of endogenous testosterone, generally known as hypogonadism.

### **Bioidentical Hormones Product Type Insights**

The Bioidentical Hormones Market segmentation, based on product type, include tablets and capsules, creams and gels, injectables, and patches and implants. The tablets and capsules segment dominated the market, accounting for 46.5% of market revenue (1.0 Billion). Due to patients' shifting preferences towards convenient dose forms and convenience of administration, the tablet and capsule sector is anticipated to dominate the market. One of the most popular estrogen replacement treatment (ERT) types is an oral medication, which is driving up demand for estradiol and additional lab tablets.

Several major producers are producing estrogens, progestins, and mixed hormones in the form of capsules and tablets to meet the rising demand. The creams and gels market is projected to expand at a major growth rate throughout the projected period due to the launch of novel gel formation therapies that perform more efficiently with no risk in the treatment.

**Figure 1: Bioidentical Hormones Market by Product Type, 2022 & 2032 (USD Billion)**

****

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

### **Bioidentical Hormones End-User Insights**

The Bioidentical Hormones Market segmentation, based on end-user, includes clinics and hospitals. The hospital segment controls the bioidentical hormones market. This is due to the fast-evolving healthcare system and abundant facilities offering worldwide bioidentical hormone therapy. Several pharmaceutical companies are also making significant investments in the area and promoting their bioidentical hormone products among hospitals by employing various marketing techniques. The clinic's segment's expansion can be due to these facilities' lower costs than other healthcare facilities, like hospitals.

### **Bioidentical Hormones Regional Insights**

By region, the study provides market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American bioidentical hormones market area will dominate this market. Due to the rising frequency of illnesses related to menopause and growth hormone deficiency and the high knowledge of the therapy among patients aged 35 and older, North America is predicted to dominate the global market. Nearly half of all post-menopausal women in the United States reported using bioidentical hormone therapy at least once throughout their lives, according to the National Institutes of Health (NIH).

Further, the major countries studied in the market report are US, Canada, France, German, Italy, UK, Spain, Japan, China, Australia, India, South Korea, and Brazil.

**Figure 2: BIOIDENTICAL HORMONES MARKET SHARE BY REGION 2022 (USD Billion)**

****

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

Europe’s bioidentical hormones market accounts for the second-largest market share due to increased growth hormone abnormalities, [hypothyroidism](../../../reports/hypothyroidism-market-6958) in the elderly population, and hormonal disorders in women experiencing menopausal symptoms. Additionally, the increased development of new pharmaceuticals by manufacturers to extend the market globally has stoked the need for drugs in a particular region driving the industry's expansion. Further, the German bioidentical hormones market held the largest market share, and the UK bioidentical hormones market was the rapidly growing market in the European region.

The Asia-Pacific Bioidentical Hormones Market is expected to grow at the fastest CAGR from 2023 to 2032. The prevalence of vasomotor symptoms linked with menopause has been observed to range from 43% to 83% among women in East Asian countries, according to Journal of the North American Menopause Society (May 2022). The region's demand for bioidentical hormone therapy is thus anticipated to increase as more women enter menopause. Moreover, China’s bioidentical hormones market held the largest market share, and the Indian bioidentical hormones market was the rapidly growing market in the Asia-Pacific region.

## **Bioidentical Hormones Key Market Players & Competitive Insights**

Leading market players are largely investing in research and development to expand their product lines, which will help the bioidentical hormones market, grow even more. The launch of new products, larger-scale mergers and acquisitions, contractual agreements, and collaboration with other organizations are significant market developments in which market participants engage to increase their global presence. The bioidentical hormones industry must provide affordable products to expand and thrive in a more competitive and challenging market environment.

One of the major business strategies manufacturers use in the global bioidentical hormones industry to increase the market sector and benefit customers is local manufacturing to lower operational costs. In recent years, the bioidentical hormones industry has stipulated some of the most important medicinal benefits.  Major players in the bioidentical hormones industry, including BioTE Medical, Bio station, Neuva Aesthetics, Advantage Pharmaceuticals Inc., SottoPelle, and others, are funding operations for research and development to boost market demand.

Theramex is a London-based pharmaceutical firm specializing in women's health goods such as contraception, fertility, menopause, and osteoporosis. It was founded in 2018 to acquire certain Teva Active Pharmaceutical Ingredients' assets belonging to Theramex Laboratories, a pharmaceutical firm in Monaco. In September 2021, Theramex announced the approval of Bijuva / Bijuve (1mg estradiol / 100mg progesterone) in Europe and the United Kingdom.

The first and only body-identical hormone therapy (HRT) medication, known as Bijuva (Bijuve in the UK), combines progesterone and estradiol in a single daily oral capsule to treat the symptoms of estrogen insufficiency in postmenopausal women with a functioning uterus and a minimum of 12 months since their last menstrual period.

I-MAB Biopharma Co., Ltd. is a pharmaceutical product development and manufacturing company. I-Mab Biopharma is a Chinese clinical-stage biotech startup that plans to IPO on the Nasdaq in January 2020. Its first commercial medicine will likely be eftansomatropin, a long-acting growth hormone with a huge market in China among pediatric patients with low height, and will be available in 2024 or 2025. In November 2021, I-MAB Biopharma Co., Ltd. collaborated with Jumpcan Pharmaceutical Group to develop and market eftansomatropin alfa (TJ101) in China.

TJ101 is a long-lasting recombinant form of human growth hormone that is now being investigated in a phase 3 clinical trial for treating pediatric growth hormone deficiency.  This agreement is intended to help it strengthen its position in the market for bioidentical hormone therapy.

### **Key Companies in the bioidentical hormones market include**

- SottoPelle
- BioTE Medical
- Advantage Pharmaceuticals Inc.
- Full Life Wellness Center
- Neuva Aesthetics
- Defy Medical
- [Bio station](https://thebiostation.com/bioblog/bioidentical-hormone-treatment-all-you-need-to-know/)

## **Bioidentical Hormones Industry Developments**

**April 2023 **Novo Nordisk announced that the FDA had approved a new indication for Sogroya (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg for the treatment of children aged 2.5 years and older who have growth failure because of insufficient endogenous [growth hormone](../../../reports/human-growth-hormone-market-6494) secretion. Thanks to this new indication, Sogroya is now the first and only once-weekly growth hormone (GH) treatment for children and adults.

**June 2022 **Astellas Pharma Inc. announced the submission of a New Drug Application (NDA) for fezolinetant to US Food and Drug Administration. Fezolinetant is a nonhormonal oral chemical under research for treating moderate to severe vasomotor symptoms (VMS) associated with menopause. VMS, characterized by hot flashes or night sweats, is a frequent menopausal symptom.

## **Bioidentical Hormones Market Segmentation**

### **Bioidentical Hormones Type Outlook**

- Estrogens
- Progesterone
- Testosterone

### **Bioidentical Hormones Product Type Outlook**

- Tablets and Capsules
- Creams and Gels
- Injectable
- Patches and Implants

### **Bioidentical Hormones End-User Outlook**

- Clinics
- Hospitals

### **Bioidentical Hormones Regional Outlook**

## Market Drivers

### Growing Awareness of Hormonal Health

{"k"=>"对激素健康的日益关注", "v"=>"围绕激素健康的日益关注是生物相似激素市场的一个关键驱动因素。随着人们对激素失衡影响的了解加深，对有效治疗方案的需求也在上升。这种意识通常受到教育活动和数字平台上信息传播的推动。因此，医疗服务提供者正目睹关于生物相似激素疗法的咨询激增。报告显示，生物相似激素市场预计在未来几年将以约8%的复合年增长率（CAGR）增长，反映出对个性化激素治疗的高度兴趣。这一趋势表明，随着越来越多的人寻求激素问题的解决方案，生物相似激素市场可能会显著扩展。"}

### Aging Population and Hormonal Changes

{"k"=>"老龄化人口与激素变化", "v"=>"向老龄化人口的转变是影响生物相似激素市场的一个关键因素。随着人们年龄的增长，他们常常经历激素变化，这可能导致各种健康问题，包括女性的更年期和男性的男性更年期。这一人口趋势预计将推动对生物相似激素疗法的需求，因为老年人寻求缓解与激素下降相关的症状。数据显示，到2030年，65岁及以上的人口预计将达到15亿，为激素替代疗法创造了一个可观的市场。生物相似激素市场有望从这一不断增长的细分市场中受益，因为医疗服务提供者越来越多地推荐生物相似选项来解决与年龄相关的激素失衡。"}

### Shift Towards Natural Treatment Options

{"k"=>"向自然治疗选项的转变", "v"=>"消费者对自然治疗选项的明显转变是生物相似激素市场的重要驱动因素。许多人因对合成激素疗法的副作用和长期健康影响的担忧而感到失望。生物相似激素源自自然来源，被视为更安全的替代方案，符合人们对整体和自然健康解决方案日益增长的偏好。这一趋势在市场数据中得到了反映，数据显示，生物相似激素的需求正在增加，特别是在注重健康的消费者中。随着越来越多的人寻求自然疗法，生物相似激素市场可能会经历持续增长，这一增长受到消费者对更安全、更自然治疗方式的偏好的推动。"}

### Advancements in Hormone Therapy Research

{"k"=>"激素治疗研究的进展", "v"=>"激素治疗研究的持续进展正在推动生物相似激素市场的发展。科学研究不断探索生物相似激素的有效性和安全性，导致改进的配方和给药方法。这些进展不仅提高了治疗的有效性，还促进了医疗专业人员和患者的更大接受度。研究表明，创新的给药系统，如经皮贴片和皮下植入物，正在获得关注，使生物相似激素疗法更加可及和用户友好。随着研究继续验证生物相似激素的益处，市场可能会扩展，受到从业者和患者对这些疗法的信心增加的推动。"}

### Regulatory Support for Bioidentical Hormones

{"k"=>"对生物相似激素的监管支持", "v"=>"对生物相似激素的监管支持正在成为生物相似激素市场的重要驱动因素。随着监管机构认识到这些疗法的重要性，支持其开发和使用的框架正在不断增长。这种监管支持不仅增强了生物相似激素的可信度，还鼓励制药公司投资于研究和开发。最近旨在简化生物相似激素产品审批流程的举措表明，市场增长的环境更加有利。随着监管的演变以适应生物相似激素的独特特性，生物相似激素市场可能会受益于产品可用性和消费者信任的增加。"}

## Future Outlook

预计生物相似激素市场将在2025年至2035年间以5.7%的年均增长率增长，推动因素包括消费者意识的提高、人口老龄化和激素治疗的进步。客户的信任增加、持续的研究与开发以及电子商务平台的兴起巩固了生物相似激素的销售。这为生物相似激素市场的稳定未来提供了保障。

到2035年，生物相似激素市场预计将强劲，反映出显著的增长和创新。

## Segment Insights

### 按类型：雌激素（最大）与睾酮（增长最快）

生物相似激素市场按类型显示出动态细分，雌激素因其在激素替代疗法和[更年期治疗](https://www.marketresearchfuture.com/reports/menopause-treatment-market-4579)中的应用而占据最大市场份额。该细分市场吸引了广泛的人群，特别是经历激素变化的女性，这显著推动了它们的需求。与此同时，睾酮作为增长最快的细分市场正在崛起，受到男性和女性对激素疗法认识和接受度提高的推动，旨在解决激素失衡并提升生活质量。

雌激素：（主导）与睾酮（新兴）

雌激素在生物相似激素市场中占据主导地位，以其在治疗更年期及相关症状中的广泛应用而闻名。这种激素不仅有助于缓解潮热和情绪波动，还在维持女性骨密度和整体健康方面发挥着至关重要的作用。相比之下，睾酮在市场上迅速崛起，归因于其在增加肌肉质量、能量水平和性欲方面的益处日益受到认可。睾酮疗法的兴起，曾经仅与老年男性相关，现在也扩展到女性，拓宽了市场格局，并鼓励医疗专业人士考虑为更广泛的患者群体提供生物相似选择。

### 按产品类型：片剂和胶囊（最大）与乳膏和凝胶（增长最快）

在生物相似激素市场中，产品类型细分展示了多样的给药机制，片剂和[胶囊](https://www.marketresearchfuture.com/reports/capsule-market-2633)引领市场。该细分市场占据了重要份额，受益于其便利性和消费者的广泛接受。紧随其后的是乳膏和凝胶，由于其易于使用和良好的吸收率而获得关注。每种产品类型的受欢迎程度因消费者偏好和预期治疗效果而异。该细分市场的增长趋势表明，乳膏和凝胶的受欢迎程度上升，被视为用户友好和非侵入性的激素给药选择。这一转变还受到对生物相似激素及其益处的认识增加，以及对个性化治疗解决方案的偏好的影响。随着医疗专业人士和患者寻求有效的替代传统激素疗法的选择，注射剂和贴片的需求也预计将显著增长，增强整体市场动态。

片剂和胶囊（主导）与乳膏和凝胶（新兴）

片剂和胶囊仍然是生物相似激素给药的主导形式，主要由于其在医疗提供者和患者中建立的存在和熟悉度。这些形式允许精确剂量，并且具有更长的保质期，使其成为长期激素治疗的可靠选择。另一方面，乳膏和凝胶作为受欢迎的替代品迅速崛起，特别是对于那些偏好非侵入性方法的人。这些外用形式不仅提供了剂量灵活性，还吸引了希望避免针头的患者。两个细分市场的价值满足了多样化的消费者需求——片剂和胶囊强调便利性和熟悉度，而乳膏和凝胶则突出了易于使用和个性化，反映了激素治疗中偏好的变化。

### 按最终用户：诊所（最大）与医院（增长最快）

在生物相似激素市场中，诊所目前占据最大的市场份额，利用其个性化的激素治疗方法。这些设施提供满足个别患者需求的定制治疗，促成了其显著的市场主导地位。相比之下，医院在生物相似激素领域的参与正在扩大，随着对全面护理的偏好增加，其市场份额也在增长，以应对激素失衡。这一趋势展示了患者越来越信任医院环境进行激素治疗，从而改变了患者治疗环境的动态。

诊所（主导）与医院（新兴）

诊所在生物相似激素市场中代表主导细分，专注于个性化治疗计划，深入研究患者的特定激素失衡。它们与医疗中的更个人化的关怀方式相关联，允许持续监测和调整，深受寻求激素优化的患者欢迎。另一方面，医院被视为新兴细分，因其能够将生物相似激素治疗整合到更广泛的医疗服务中而迅速获得关注。患者通常将医院视为包括激素治疗在内的全面医疗的可靠选择，受到协调的多学科护理需求的驱动。对医院协议和安全措施的信心不断增强，使其有望进一步增长。

## Regional Market Share Analysis

### 北美：生物相似激素市场的领导者

北美是生物相似激素的最大市场，占全球市场份额的约60%。该地区的增长受到对激素替代疗法认识的提高、激素失衡发生率上升和支持性监管框架的推动。个性化医疗的需求和复合药房实践的进步进一步催化了市场扩展。由于成本显著低于美国——通常低50%——以及在蒂华纳和坎昆等城市集中了一些专业诊所，墨西哥的生物相似激素替代疗法（BHRT）也在增长。

美国是主要贡献者，关键参与者如AbbVie、赛默飞世尔科技和BioTE Medical在竞争格局中处于领先地位。先进的医疗基础设施和日益增长的老年人口也促进了市场增长。加拿大紧随其后，成为第二大市场，约占整体份额的15%，并专注于创新治疗方案。

### 欧洲：具有增长潜力的新兴市场

欧洲的生物相似激素市场正在显著增长，占全球市场份额的约25%。增长受到健康意识提高、老龄化人口和对激素疗法接受度增加的推动。监管机构也在促进生物相似激素的使用，从而增强市场动态。德国和英国在这一增长中处于领先地位，得益于有利的医疗政策。德国是欧洲最大的市场，受益于强大的医疗系统和对个性化治疗的高需求。英国紧随其后，越来越多的诊所提供生物相似激素疗法。拜耳和迈兰等关键参与者正在积极扩大在该地区的存在，促进了一个促进创新和可及性的竞争环境。

### 亚太地区：快速增长的市场细分

亚太地区正在成为生物相似激素市场的重要参与者，目前占全球市场份额的约10%。增长受到医疗支出增加、对激素健康认识提高和老龄化人口增长的推动。澳大利亚和日本在前沿，政府支持的倡议促进了先进医疗解决方案。澳大利亚在该地区的市场领先，重点关注激素疗法的研究和开发。日本紧随其后，对个性化医疗的需求不断增长。竞争格局由本地和国际参与者共同构成，包括HRT和SottoPelle等公司，它们正在扩大产品以满足对生物相似激素日益增长的需求。

### 中东和非洲：具有独特挑战的新兴市场

中东和非洲地区的生物相似激素市场正在逐步发展，目前占全球市场份额的约5%。增长主要受到医疗投资增加、对激素疗法认识提高和寻求先进医疗解决方案的人口增长的推动。然而，监管挑战和不同的医疗标准对市场扩展构成了障碍。南非和阿联酋等国在市场中处于领先地位，专注于改善医疗基础设施和获取创新治疗。竞争格局正在演变，本地参与者和国际公司正在探索该地区的机会。关键参与者的存在仍然有限，但随着对生物相似激素的认识和接受度提高，增长潜力显著。

## Competitive Benchmarking

生物相似激素市场目前的特点是动态竞争格局，推动因素是消费者对激素治疗的认识提高和对个性化医疗解决方案的需求增长。关键参与者如AbbVie（美国）、拜耳（德国）和BioTE Medical（美国）通过创新和合作伙伴关系战略性地定位自己。AbbVie（美国）专注于扩展其产品组合，特别是在激素替代疗法方面，而拜耳（德国）则强调研发以增强其在女性健康领域的产品。BioTE Medical（美国）利用其在复合方面的专业知识提供量身定制的激素解决方案，从而增强其市场存在感。这些策略共同促进了一个越来越关注个性化治疗选择和以患者为中心的护理的竞争环境。在商业策略方面，公司越来越多地本地化生产并优化供应链，以提高效率和响应市场需求。生物相似激素市场似乎适度分散，既有成熟的制药巨头，也有专业的复合药房。这种结构允许提供多样化的产品和服务，以满足不同消费者的需求，同时促进关键参与者之间的竞争。2025年8月，AbbVie（美国）宣布与一家领先的远程医疗提供商建立战略合作伙伴关系，以增强激素治疗咨询的可及性。这一举措具有重要意义，因为它与数字健康解决方案的增长趋势相一致，使AbbVie能够接触更广泛的患者群体并简化治疗过程。远程医疗服务的整合可能会提高患者参与度和治疗依从性，从而可能增加市场份额。2025年9月，拜耳（德国）推出了一系列专为绝经女性设计的生物相似激素产品，强调其生产过程的可持续性。这一举措不仅满足了市场的关键需求，还反映了拜耳对环保实践的承诺。这些产品的推出可能会通过吸引环保意识强的消费者来增强拜耳的竞争优势，从而使公司在一个越来越重视可持续性的市场中处于有利地位。2025年7月，BioTE Medical（美国）通过与美国各地的多家健康诊所建立合作伙伴关系，扩大了其分销网络。这一战略举措至关重要，因为它使BioTE能够增强其覆盖面和可及性，特别是在服务不足的地区。通过扩大其市场足迹，BioTE可能会捕获更大市场份额，有效响应对生物相似激素疗法日益增长的需求。截至2025年10月，生物相似激素市场正在见证数字化、可持续性和人工智能在治疗方案中的整合等趋势。公司之间的战略联盟正在塑造竞争格局，促进创新并增强服务交付。展望未来，竞争差异化似乎将越来越依赖于技术进步和供应链可靠性，逐渐远离传统的基于价格的竞争。优先考虑创新和以患者为中心的解决方案的公司可能会在这一不断发展的市场中蓬勃发展。

## Recent News & Developments

**2023年4月**，诺和诺德宣布FDA已批准Sogroya（somapacitan-beco）注射剂5毫克、10毫克或15毫克的新适应症，用于治疗因内源性[生长激素](../../../reports/human-growth-hormone-market-6494)分泌不足而导致生长失败的2.5岁及以上儿童。由于这一新适应症，Sogroya现在是儿童和成人的首个也是唯一的每周一次的生长激素（GH）治疗。

**2022年6月**，Astellas Pharma Inc.宣布向美国食品和药物管理局提交了一项新药申请（NDA），用于fezolinetant。Fezolinetant是一种非激素口服化合物，正在研究用于治疗与绝经相关的中度至重度血管运动症状（VMS）。VMS以潮热或夜间出汗为特征，是一种常见的绝经症状。

## Report Scope

| MARKET SIZE 2024 | 2.37(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 2.505(USD Billion) |
| MARKET SIZE 2035 | 4.362(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.7% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | AbbVie (US), Bayer (DE), Thermo Fisher Scientific (US), Mylan (US), HRT (US), BioTE Medical (US), SottoPelle (US), Compounding Pharmacy of America (US), Women's Health Network (US) |
| Segments Covered | Types, Product Types, End Users, Region |
| Key Market Opportunities | Growing consumer demand for personalized hormone therapies drives innovation in the Bioidentical Hormones Market. |
| Key Market Dynamics | Rising consumer demand for personalized healthcare drives innovation and competition in the bioidentical hormones market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation for the Bioidentical Hormones Market in 2035?**
A: The Bioidentical Hormones Market is projected to reach approximately 4.362 USD Billion by 2035.

**Q: What was the market valuation for the Bioidentical Hormones Market in 2024?**
A: In 2024, the Bioidentical Hormones Market was valued at 2.37 USD Billion.

**Q: What is the expected CAGR for the Bioidentical Hormones Market from 2025 to 2035?**
A: The expected CAGR for the Bioidentical Hormones Market during the forecast period 2025 - 2035 is 5.7%.

**Q: Which companies are considered key players in the Bioidentical Hormones Market?**
A: Key players in the Bioidentical Hormones Market include AbbVie, Bayer, Thermo Fisher Scientific, Mylan, HRT, BioTE Medical, SottoPelle, Compounding Pharmacy of America, and Women's Health Network.

**Q: What are the estimated market values for Estrogens in the Bioidentical Hormones Market?**
A: The estimated market values for Estrogens range from 0.95 to 1.75 USD Billion.

**Q: How do the market values for Tablets and Capsules compare to other product types in the Bioidentical Hormones Market?**
A: Tablets and Capsules are valued between 0.75 and 1.4 USD Billion, making them a leading product type compared to others.

**Q: What is the market value range for Progesterone in the Bioidentical Hormones Market?**
A: The market value range for Progesterone is estimated between 0.75 and 1.25 USD Billion.

**Q: What are the projected market values for clinics and hospitals as end-users in the Bioidentical Hormones Market?**
A: Clinics and hospitals are projected to have market values ranging from 1.185 to 2.186 USD Billion and 1.185 to 2.176 USD Billion, respectively.

**Q: What is the estimated market value for Testosterone in the Bioidentical Hormones Market?**
A: The estimated market value for Testosterone ranges from 0.67 to 1.32 USD Billion.

**Q: How do the market values for creams and gels compare to injectables in the Bioidentical Hormones Market?**
A: Creams and gels are valued between 0.5 and 1.0 USD Billion, while injectables range from 0.62 to 1.1 USD Billion, indicating a competitive landscape.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/bioidentical-hormones-market-4187*